MOTYS™  »  Preclinical  »  Clinical  »  Pipeline

Phase 3-ready biologic:

Doron Therapeutics | Motys | Logo

Derived from placental tissues, MOTYS™ is a biologic therapeutic classified as a Regenerative Medicine Advanced Therapy (RMAT).

Effects from a single intra-articular injection of MOTYS™ last 9-12 months — no other treatment is this potent.

Pro-anabolic

New tissue formation through cell recruitment, differentiation, and/or proliferation

Anti-catabolic

Mitigation of cartilage degeneration

Anti-inflammatory

Reduction of pain and swelling

Harnessing the power of the placental secrotome

  • Immunologically inert placental tissue
  • Sourced from rigorously screened donations after planned, healthy
    C-section births
  • Proprietary process conserves and concentrates the stem cell secrotome
  • Consistently rich in extracellular matrix, growth factors, and signaling molecules
  • Cell free, terminally sterilized, refrigerator stable formulation
  • Rigorous and proprietary controls ensure consistent, reproducible potency of final formulation

Remarkable Potential

MOTYS™ holds great potential as a biologic therapy, because it displays a multifactorial mechanism of action (MOA). This MOA may promote a beneficial combination of anti-inflammatory, anti-catabolic and pro-anabolic effects. These effects have been demonstrated through in vitro and in vivo data in a range of applications.

Reliable Consistency

MOTYS™ was developed with a goal of providing a more consistent amniotic option. Through careful recovery, specialized processing and testing, MOTYS™ has demonstrated lot-to-lot consistency of naturally occurring biofactors.

 

MOTYS™ is:

Sterile, containing
no live cells

Stored at room
temperature

Easy to
reconstitute

Contact Us

Our team can help to answer any of your questions.
Get in touch to learn more about Doron Therapeutics.

Contact Us